Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

Still needs a bit of tweaking mate but getting there.
You will need to remap the charts to moneyam as the advfn ones don't come up unless you are logged in to advfn aswell

Sorted!

More great news today!

The Company was informed on 12 December 2005 by Schroder Investment Management
Limited that it has an interest in 17,224,284 ordinary shares of 0.1 pence each
in Osmetech, representing approximately 13.07 per cent. of the Company's issued
ordinary share capital.

14 December 2005

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

Found this interesting little PDF about the OPTI-CCA.
It gives some more close up detail and information on how it works and a list of the some of the organisations in the UK using it.
Interstingly BUPA have 17 of them, perhaps there is great potential here for pushing the rest of Osmo product line.


http://www.bio-stat.com/files/downloads/26.pdf

Interestingly Gordon Hall was previously a director of Biostat and nodoubt will maintain connections with them.

Osmetech GMBH are starting to get a little more exposure as well.
http://www.notfalllabor.de/Osmetech-GmbH/40-0-0-0-94-0-0-O.html

Share price continuing its pre new year advance. Looking good for the trading update.

Here's the first outing for the company in 2006.

ARAB HEALTH / MEDLAB Exhibition
http://www.arabhealthonline.com

Dubai International Exhibition Centre
Dubai, UAE January 22-25, 2006


http://www.arabhealthonline.com/index.cfm?page=exhibitor_details&menuid=&RecordNo=1&id=4659&type=alphabet&c=O&option=&keyword=&style=1

So OMH gets a bronze cup for last months performance in the To Double Competition thanks to those that have left comments

Anyone got todays Investors Chronicle? It would appear that the highly respected magazine has given OMH a favourable mention!

From the IC website:

OSMETECH (OMH)

Thanks to acquisitions, Osmetech has built up an impressive portfolio of biological testing equipment. It started off with an...

EDIT
"Osmetech's tactic of buying non-core assets is paying off, Medium-term Buy"

With the price having reached EVO's stingy target of 26p it was only fair of them to update to a new stingy target. Still 36p will do for starters.

Perhaps a trading update is now less likely?

Here's a taster for the full report go to EVO Website
2006 holds much promise


2006 stands to be a strong year for Osmetech. Management has built a strong
product pipeline, which should drive a strong start to 2006 with the anticipated
1H06 launches of OPTI GENE, OPTI TUBE and Thrombosis Risk Marker tests and
the eSensor and cystic fibrosis test. The company has stoked interest in its initial
molecular diagnostics offering in the lead up to their 1H06 launch at the
November 2005 AMP and Medica industry meetings as evidenced from the
positive reception. In addition, the full period impacts of previous launches with
their attractive recurring consumable stream will further drive performance.

Very positive trading statement out this am. OMH is positive FDA approval on CF eSensor test will be concluded within weeks.

Full text
http://moneyam.uk-wire.com/cgi-bin/articles/200601190700161246X.html

How long before we reach the EVO target this time? The last couple of EVO targets were reached within in a couple of weeks of them announcing it.

"We are confident of receiving FDA approval for its eSensor instrument and cystic fibrosis (CF) test within the next few weeks, which would be a first for a combined instrument and consumable CF assay."

If this happens in the next couple of weeks 36p will be passed at the speed of light

More to the point whats NEW ADVISER Hoare Govett's target going to be??

A good move getting rid of EVO as their reputation alone would deter some investors.

FDA Approval Granted!

EXCELLENT NEWS

FDA approval

RNS Number:3456X
Osmetech PLC
24 January 2006

24 January 2006


Osmetech plc receives FDA clearance for its cystic fibrosis molecular
diagnostics test


Osmetech plc, the international healthcare diagnostics group, has received its
510(k) clearance from the US Food & Drug Administration ('FDA') for its cystic
fibrosis ('CF') carrier detection test and its eSensorTM4800 DNA Detection
instrument platform. Sales of the instrument and CF test will commence in the
first half of 2006 as planned.


James White, CEO Osmetech plc said, 'Gaining FDA clearance for our first
microarray based test developed for our new eSensorTM molecular diagnostics
instrument is a major step forward for our Molecular Diagnostics Division and
will help to establish Osmetech as a key player in the fast growing molecular
diagnostics market. In addition, this FDA clearance helps to validate our
microarray technology for routine use in the laboratory.


'Following the approval of the eSensorTM platform we now look forward to
progressing discussions with strategic partners who are looking for cost
effective and easy to use instrumentation and consumables to work on other
complex assays both in the healthcare and non healthcare markets. The next
Osmetech Molecular test targeted for FDA submission will be our CYP 450
pharmacogenomics assay, which is currently in development.'


Background information on Cystic Fibrosis

With a carrier frequency of one in 25 and an incidence of one in 2,500, Cystic
Fibrosis is the most commonly inherited disease in the North American Caucasian
population. The American College of Medical Genetics and the American College of
Obstetricians and Gynaecologists recommended in 2001 that Cystic Fibrosis
carrier testing should be made available for all reproductive couples. Currently
around one million tests are carried out annually in the US alone.


Most current tests are not FDA approved and testing locations are restricted to
those 300 institutions which are CLIA approved for running complex testing where
the testing institution is responsible for regulatory obligations rather than
the diagnostic company. The tests carried out in the large central laboratories
are performed on instruments that can cost in the region of US$100,000 and a
high throughput is required to justify the capital cost of the equipment. In
addition the instruments are operated by qualified technicians capable of
interpreting the results. As a result of this each test is relatively expensive
with each test recharged at up to US$400 per test to those small to medium sized
hospitals requesting the tests to be run on their behalf.



Ends


Enquiries:
Osmetech plc: James White/David Sandilands 020 7849 6027
Madano Partnership: Matthew Moth/Mark Way 020 7593 4000




Notes to editors:

Background on the Molecular Diagnostics Market

Molecular diagnostics is the fastest growth segment of the global diagnostics
market with annual growth rates in excess of 20%.

The benefits of molecular diagnostics are that it can provide highly accurate
testing, the possibility of earlier detection of infectious diseases and can
identify patients with a predisposition for certain diseases such as cystic
fibrosis and certain cancers. This provides the facility for earlier
intervention of therapy thereby facilitating improved treatment success rates.

Molecular diagnostics can also enable physicians to pre-determine drug dosages
and monitor the effectiveness of such treatments for individual patients and
also aid the avoidance of toxicity or adverse drug reactions.



The two main growth drivers for the molecular diagnostics market are the Human
Genome Project and the growth of new technologies providing the opportunity for
small and medium sized hospitals to carry out tests within this market. Through
the Human Genome Project, over 30,000 genes have been sequenced. Assuming that 5
per cent. of these genes will be of diagnostic significance this would create
1,500 gene based tests.



The molecular diagnostics market today is at an early stage of development and
is characterised by expensive first generation instruments which require skilled
labour and are reliant on high throughput in order to control costs. The batch
testing performed in large laboratories and hospitals precludes the ability to
give rapid turnaround times. Whilst the common PCR technology is widely
understood Osmetech believes that the products available today do not meet the
needs of small and medium sized hospitals.



Three main sub segments account for over 75 per cent. of the US molecular
diagnostics market: Human Genetics, Pharmacogenomics and Infectious Diseases.



Human genetics focuses on enabling the physician to test individuals for
diseases for which they have a genetic predisposition, for example: cystic
fibrosis, thrombosis, Alzheimer's or certain cancers. This is achieved through
the detection of SNPs or "mistakes" in an individual's DNA which may cause the
mutations that are associated with a particular disease. This is the segment
where Osmetech is launching its first products.




This information is provided by RNS
The company news service from the London Stock Exchange
END

REAIIFIALDISFIR

Minor treeshake today. Good buying opertunity IMO

Motorola, have sold their shares in the Company (212,470,862 pre consolidation so now 21,247,086) but only got 20p each for them. 6 months to the day the earlyest they could sell them.
Exact number of the big trade today.
Buy early these will go up friday.

Good prognosis

Keep an eye on healthcare diagnostics group Osmetech. That was the word among market professionals last night after a large stock overhang was cleared. Evolution Securities placed 21m shares - around 16% of the company - at 20p on behalf of Motorola with a variety of City institutions and private client brokers. Motorola's shareholding dates back to the summer when it sold its Clinical Micro Sensors business to Osmetech. With the Motorola holding out of the way, traders were expecting the stock to rally this morning. Earlier this week Osmetech, which recently appointed Hoare Govett as its broker, received American regulatory clearance for its cystic fibrosis carrier detection test. Yesterday Osmetech shares lost 4.5p, or 14.5%, to close at 26.25p.

In other words everything is on track and dont be panicked into selling!

From todays RNS
Osmetech has no further information to add to its Trading Update of 19 January
2006 and the FDA clearance of the CMS eSensor cystic fibrosis test announced on
24 January 2006.

Ends

Double post

The Latest Wallstreet Reporter Interview with Jame White (Thanks to DP)

Osmetech firmed 0.75p to 24.5p amid talk that testing of its cystic fibrosis diagnostics kit is ahead of schedule.

Just announced.

Osmetech Plc Notice of Results
RNS Number:8280Y
Osmetech PLC
23 February 2006



Notification of Final Results announcement



Osmetech, the international medical devices and diagnostics group, is to
announce its preliminary results for the 8 months to 31 December 2005 on Tuesday
21st March 2006.



As previously announced, Osmetech has now changed to a December financial year
end. As a result there was no interim results statement for the 6 months ended
31 October 2005.



Enquiries:

Mark Way

madano partnership 020 7593 4000

Last time we had a months notice of the results was the 30 June 2003.
The price on that date was 32p. The price dropped initially to 29p on the 2nd July before recovering and hitting a peak of 50p on the 28th July.

By the time of the results on the 30 July 2003 the price had fallen back to 43p.

I made sh1t loads of money that month!

Bring it on this time!

Bangers are you running a challenge here?

Well here's the price predictions from the OMH thread on a competitors site. If there's any Osmetech share holders here that would like to join in the just post your price guess for the EOD price on the day before the results - 20th March 2006. Competition closes 16:30 today.

Guess the price EOD on the 20th Mar 06. Current Average Guess = 35.5p!!

Poster's Name Price Youcorksuckers 48p JamesDean 43.2p Tradingplenty 43p Galco 41.5p Bangers 40p Ditchpig 39.75p Bucketfull 39p Muffster 39p CHESTERONE 38.75p bcfcruleok 38.25p Canaries 38p bleunose 37.5p cricketmad 37.5p Freddyfrog 37p eurojaws 36.75p Biofish 36.5p boonyed 36.5p REDHILL 36p Protec 35.5p Jacinta 34.5p tanchos 34.25p Gerry2 34p troutisout 33.5p Hutchmeister 33p BennyTheBall 33p sequoia 33p The Explorer 32.5p lomac 31.5p Rosco 29.5p The Novice 29p PC 27.75p C Moggie 27p HoT 20p

Looks good to me. I've tipped at 39.75p though that might be a little conservative now.

Just a quick glance back over the historic chart patterns shows that OMH can and does make some huge moves prior to the results. Rises of 50 -75% have been seen in a space of the few weeks prior to the figures release.

Interestingly a poster on ADVFN has estimated that the takeout value of Osmetech could be in the region of 500m or about 3.80 a share.
That's based on the value Becton Dickinson paid for GeneOhm at 46x revenues purely revenues from their PCR buisness of $5 million. Osmetech revenues from the blood gas critical care side of the buisness already exceed $5 million and with the imminent launch of OPTIgene and eSensor Osmetech group revenues are expected to greatly exceed that figure very rapidly.

Should see a significant rise on Monday on the back of todays Telegraph write up. It seems that a few of the national papers are keeping a close eye on OMH (Osmetech)

http://www.telegraph.co.uk/money/main.jhtml?xml=/money/2006/03/18/ccmed18.xml&menuId=242&sSheet=/money/2006/03/18/ixcoms.html

New ways to cut the error out of drug trials
By Katherine Griffiths (Filed: 18/03/2006)

Better understanding of our DNA and other high-tech advances will make medical research less risky, says Katherine Griffiths

As the families of six men seriously ill from taking an experimental leukaemia drug wait anxiously for news of whether they will recover, a question doctors and the public will ask is if this tragedy could have been prevented.

The answer is, perhaps, yes. It is too early to say for certain, because it is not yet known what caused the terrible reactions in the human volunteers to the drug TGN1412. There could have been problems with the medicine, but equally it could have been someone giving the wrong dose or a toxic substance getting into its production which was to blame.

Some in the pharmaceutical and biotechnology industries say if it is the drug which turns out to have been the problem, such a tragedy might not have to be repeated. This is because tests that show to a far greater extent than ever before what a drug will do to a human before it is injected into the body are now at the cutting edge of research and development.

The wealth of new information about the way the body works from breakthrough discoveries about our DNA is making these new techniques ever more useful.

The new technologies, most of them still only being worked on by a handful of small companies around the world, which sound more like science fiction than reliable scientific tests, are rapidly being built on top of that foundation.

The methodologies range from computer modelling involving highly complex mathematics to testing drugs on hearts taken from people killed in traffic accidents and kept alive in boxes.

Analysts say these techniques are on the brink of explosive growth, with large pharmaceuticals companies waking up to the fact that they can massively speed up the drug development process and also make it much cheaper, because dud medicines can be scrapped at an earlier stage.

The devastating events at Northwick Park Hospital in north London, which have left two men in a coma and four others still seriously ill, will also inevitably act as a catalyst in getting regulators and public opinion to put pressure on drug developers to turn to new and more sophisticated tests.

Most experts in the pharmaceuticals industry believe such developments will not replace the current system, where drugs are tested in laboratories, then on animals and then in three phases of human trials.

But a growing number believe the traditional system could be greatly improved by adding a range of new tests, especially at the stage when a drug has been given to animals but not yet been introduced as a phase 1 trial in people.

Ibraheem Mahmood, a lifesciences analyst at Investec, points to the emerging field of testing unknown drugs on human organs taken from people who have died from other causes as an area of huge future significance.

"In five or 10 years' time the world's pharmaceuticals and biotechnology companies will still be running the same animal and phase 1 trials but they will also have a battery of supporting tests that provide greater insight into the results of these tests. We'll be able to make much better decisions before committing to large and expensive risky trials," Mr Mahmood said.

One developer of this technique, known as "ex vivo", is a small company called Asterand, which is operating in both both Detroit in the United States and Royston, Hertfordshire, a few miles south of Cambridge.

The company takes tissue from a variety of sources, including accident victims, and from people who have donated their organs which turn out not to be good enough, and either supplies them to drugs companies for tests or does the tests itself.

Ronald Openshaw, Asterand's chief financial officer, said TeGenero, the German company which made TGN1412, was not a client, so it was impossible to tell exactly what tests were done on the drug apart from the animal tests required by regulators before the drug was tried out in humans.

But he said: "That whole bitterly disappointing situation raises the issue of if there was anything else that could have been done."

Mr Openshaw argues that Asterand's technology does, at least in some circumstances, catch such situations. He cited the example of a client which had brought a drug to Asterand for testing.

"The drug had been in pre-clinical development and they thought it caused cardiac toxicity.

"We took some heart muscle and put it in an organ bath where it could be kept beating and effectively alive for three days. We tested the drug on it and found it did have side effects," Mr Openshaw said.

Asterand will not reveal the identity of the company because it keeps all of its clients confidential, but it did say it was a large player in the pharmaceuticals sector which, after it received the results of the trial from Asterand, dropped the drug.

Asterand, which has just 100 employees and has been gradually developing its techniques for the past eight years, says it is now being overwhelmed with demand from large drug companies that want to use its techniques.

Another arena where small developmental companies are finding themselves in demand is in an area known as molecular diagnostics. Thanks to the wealth of information now available about the human genome, companies can work out with far greater precision what a drug will do to a particular person based on their genetic make-up.

A company working in this area is the Boston-based Osmetech. Among the products the company has developed is something called an Esensor, a machine which uses DNA technology.

It is also developing something called an Optigene, a piece of equipment slightly bigger than a laptop computer which will help scientists in labs and doctors in hospitals find information such as a person's metabolism. Such relatively simple information can make a lot of difference in deciding on what dose to give a patient and even whether the medicine will work at all.

The reasons why these areas are some of the fastest growing in the drugs industry are not hard to find. Pharmaceutical companies have to pay more than 500m to bring a single drug from its earliest stages through a multiplicity of tests to the market.

Adopting tests that can determine at an early stage whether the treatment will work in humans or not could save millions of pounds. It is possible that it could also save lives.

16 March 2006[News]: Drug trial victim is like Elephant Man, says girlfriend

Any rise will be down to the results due on Tuesday not an article in the Telegraph.

astonvilla

Watch and learn...it's called DYOR...great find bangersmam.

astonvilla - squelched

yeah good post bangers but why will the share price be affected by an article in Telegraph 1 day before results with only a small mention to OMH? You said a significant rise. Lots of interesting posts and research on a competitors message board which you are a member. DYOR and dont ramp with outrageous comments. OMH are establishing a sound product base with sales. This share price will only go one way and that is up. DYOR.....update......where was this substantial rise....mid price never moved? Lets hope tomorrows results raise the profile of OMH. I've topped up.

Results Out On Tuesday

Ditchpig..are you sure?

Results are out.....can anyone post results or link for others. Results as expected for me but sp dropping. Bringing new products to the market is expensive, so always going to need additional funding. DYOR and dont listen to rampers like Bangersmam and his posts on other sites. Substantial rise get real. Sound management establishing a good solid platform for growth never going to be a quick buck made here. I continue to hold.

As a holder of this stock for over four years, I'm very glad I sold out at the recent peak of around 34p (nursing a chunky loss, too). I'm afraid to say that I have been disappointed with this share since the "story" changed quietly some time back from selling a Chlamydia test based on the "electronic nose technology" into a multi-billion-dollar market to the current concentration on Gene products. (The Chlamydia product appears to have been rendered superfluous by a home-testing product developed by a rival; it's a pity OMH didn't see this coming sooner). A lot of dilution has been involved in the process of OMH acquiring new products and for those of us who bought most of our stock pre-consolidation, that has meant that the attractiveness of the share has dwindled greatly over time. While I am certain that OMH's new product range will have its day in the sun, it is clear that a lot more dilution is in the pipeline as they place stock in order to fund the co through to profitability.

This share would have to take a well-deserved hammering before I could be induced to buy again. Perhaps a visit to the recent low of around 15p is too much to ask, but I would only think of the SP as attractive around 18p and then as a speculative bet rather than a near certainty. Longer-term I'd incline towards agreeing with astonvilla, but so far it has been a bumpy ride and more than likely will be in the future.

All IMHO, PDYOR, etc., and good luck to those of you who are still in!!

Like Soul traders, I have been in this stock for a few years, hoping with some enthusiam that their products were at the forefront of technology and rich pickings were there for the brave.

Trouble is that the management keep moving the goalposts promising jam tomorrow and continually look for acqusitions without fully bedding down previous buys. Perhaps the markets reaction today will remind the management that it is a fickle world out there and they will be continually penalised in the SP when they dont deliver.

Good comment, hobbsts - hope you haven't bet your pension fund on this one!! :o)

What a group of pathetic, short sighted, moaning, old whingebags.



Yes the company has stated they may require further funding to take them in to profit BUT they have also made clear this may come from a variety of ways. NOT necessarily by further dilution of the SP.

As for not bedding in previous acquisitions??? I think we can now say OPTI is firmly bedded in with the help of a 10 year agreement with IDEXX, and the recently purchased MOLs and CMS technology is only a few months away from hitting the market in it new form...... The same technology which is currently being applied to a new platform at IDEXX which will be an instant worldwide hit to be launched in the short / medium term. Not to mention the chance of the technology being used in alternative markets - forensics, environmental etc...........................zzzzzzzzzzzzzzzzzzzzz

For those that haven't bothered to read further than the results headlines - News flow over the next few months will be very strong.

1) CMS eSensor - launch date: April 2006
2) OPTI TUBE - launch date: May 2006
3) OPTI GENE - launch date: June 2006

These products were exhibited in
November 2005 at two major international shows in the US (AMP) and Europe
(Medica) and generated a significant level of pre-launch interest both from
potential commercial partners and end customers.

Nope - thank god for my final salary pension!!

Am showing a hefty loss on Osmetech and have put it down to experience .... you win some , you lose some. Will hold in the forlorn hope that the management can find some profit within their little empire, but the continued promise of success has worn very thin with me, but I least I still can have a giggle every time they release their results !!!

I think it is a shame Bangersmam when you have some investors who share a different view to yours you have to call them pathetic..Who was the one that mentioned a significant rise a few days ago?..ummm grow up. I'm not disputing what you say but you ramp a share too much here and on a competitor board. The last few posts by observers and investors are well judged there are no quick bucks here but I for one also remain positive about the future albeit not as quick as we would all like.

Yaaaawwwwwwwwwn

The lunch time AFX update


LONDON (AFX) - British diagnostics group Osmetech PLC reported widening
losses in the last 8 months of 2005 after buying molecular diagnostics group
Clinical Micro Sensors (CMS) last year.
Osmetech is reporting 8 month results after changing its year end date. In
the 8 months ended Dec 31 pretax losses widened to 5.4 mln stg from a loss of
2.9 mln in the 12 months ended April 30, 2005.
CMS accounted for 2.9 mln stg of the losses, and Osmetech said group loss
will increase this year reflecting a full year's effect of the new business.
The company is due to launch three new products in the next few months, and
chief executive James White told AFX News that profitability should start to
improve as soon as they hit the market.
"We knew when we bought the business we would have to fund some working
capital, but within 6 months we've got a product ready to hit the market place,"
he said in an interview.
Osmetech has two units, critical care, which makes blood gas analysis
machines, and another that is developing molecular diagnostics equipment.
It was the latter division that was strengthened with the acquisition of CMS
last year. Its first test, to detect the gene for Cystic Fibrosis, will be
launched shortly on the new eSensor platform.
A DNA analysing system called Opti Gene and a product line for use on a
Roche AG instrument will follow.
Osmetech hopes smaller hospitals will buy the machines. They allow doctors
to carry out tests on site and more cheaply than sending away samples to a lab.
White said the market for molecular diagnostics is growing fast as more
tests are developed, and the division has the potential to be more profitable.
The distribution network already established for the critical care business
will be utilised to roll out the new products.
The group will also be looking to acquire and develop new tests, such as for
MRSA detection, the CEO added.
In the last 8 months of 2005, sales surged 78 pct to 5.59 mln stg compared
to the same period the previous year. The result was lifted by a
better-than-expected result from Critical Care.
The launch of a new machine for vets helped boost sales in 2005 by 64 pct to
14.79 mln usd. The company is not anticipating the same level of growth from the
division this year, but sales should still increase significantly and
profitability improve, it predicted.
Osmetech shares were trading 3 pence weaker at 22.25 at noon, valuing the
company at 33 mln stg.
amy.brown@afxnews.com
ab/vjt/ab/ra

COPYRIGHT

clueless tw@ts

Its the market that ultimately judges the company by its performance and future outlook. I would absolutely love OMH to rocket and make me some money, but I think people have to be realistic and not to get carried away with the jam tomorrow syndrome.

exactly Hobbsts you only have to view AD VFN message board to see what Ditchpig and Bangersmam post......if anybody is clueless its them. They abuse and ridicule people who dare to have a slightly different opinion to themselves......so what is the point of investor threads if it is not for debate, either positive or negative. i feel quite sorry for them as I have far better things to do than call people clueless ***** and pathetic. The more OMH posts here the better as I am sure Moneyam will not let this site get as abusive as AD VFN. Sorry to say like most things it is a few people that spoil it for the rest of us.

bangersmam,

not shortsighted, just opening up the debate a little. As I have said, I could be persuaded to buy more OMH, but only if I think I can see significant upside, and more than in the many other stocks I am also watching.

Ditchpig,

You'll notice that I don't make personal comments; I'm here to talk about shares. Ten-baggers, preferably.

And I'll thank you for minding your language.

Usual sell off after the results, the small short sighted PI's sell and the big boys buy. I dont think it will be long before an increased holdings RNS comes out.

My guess is that Gartmore have been loading up. Time will tell.

Presumably you were driven out of Bournemouth with pitchforks and flaming torches. Arrrr don't want none of those namby pamby 'omosexual types 'ere.

Actually it was electric cattle prods - the farmers down in Dorset aren't as backward as they're made out to be.

LOL!
arrr don't be messin wiv this ere new fangled lectric. It be witchcraft I'll tell thee.

So its confirmed - Gartmore WERE buying the shares from the likes of the above shortsighted ones.

SAR 3 - Osmetech plc

FORM SAR 3

DISCLOSURE OF ACQUISITIONS

(Rule 3 of The Rules Governing Substantial Acquisitions of Shares)

Name of acquirer Gartmore Investment Management plc

Beneficial owner, if different (Investments managed on a discretionary
from above basis)

Names of any other persons
acting by agreement or
understanding (see SAR 5)

Company dealt in Osmetech plc

Class of voting shares (eg Ordinary GBP0.001
ordinary shares)

Date of acquisition 22nd March 2006

Number of shares acquired 1,700,000

Number of rights over shares
acquired

Nature of rights over shares

Total holding of voting shares 24,084,657 (18.27%)
(and percentage of total voting
shares in issue)

Total holding of rights over
shares (and percentage of total
voting shares in issue)

Combined total holding (and 24,084,657 (18.27%)
percentage) of voting shares and
rights over shares

Casts a different light on it now.

The threads quiet today, i wonder where our most recent contributors might be??

Am sitting comfortably, still holding onto my OMH shares.

I think this thread needed a dose of realism to inject some proper debate about the future direction of the share price. Opposing views should be welcomed provided that nobody conducts personal vendettas just because they dont agree. I personally dont give a toss if someone calls me a tw@t or something similar, but it hardly adds anything meaningful to the debate.

Can only be a good thing that Gartmore have increased their stake.

Can it? State the ble@ding obvious why don't you.
zzzzzzzzzzzzzzzzzzzz
well you've really added a lot haven't you.
zzzzzzzzzzzzzzzzzzzzz

Sorry DITCHPIG, not going to drop to your level, grown-ups only.

bangersmam,

was busy watching VOG, which is what I bought when I sold my OMH. To date I've gained 14% instead of dropping 30%.

Now if you'll excuse me, I have an appointment to get myself fitted for a new white cane . . .

Yes I'm sure that's what you told the judge.

I continue to hold......if you could read english you would see our posts were about your infantile behaviour.....if anybody reads ADVFN they would see you behave the same way on that thread. My posts from now on are directed to serious traders like Hobbst and Soul traders who have objective views.

Oh I see. Thanks for letting us know.
Pity that yourself and the "serious traders like Hobbst and Soul traders " don't know the first thing about Osmetech its products, statergy or history but as you say you are just "serious traders" such things wouldn't be of interest to you.
Hope you managed to put your shorts out today before something vital got singed.
Still as they say in the Midlands.
Shit on the villa!!!

Osmetech (OMH) are tipped as a good value buy in todays Investors Chronicle.

Hot of the press

http://www.investegate.co.uk/Article.aspx?id=200603271510554570A

Osmetech PLC
27 March 2006


Osmetech plc ('Osmetech' or 'the Company')


The Company was notified on 24rd March that Gartmore Investment Ltd (GIL)
Gartmore Fund Managers Limited (GFM) and Gartmore Global Partners (GGP)
increased its reportable interest in the Company due to the purchase of
1,700,000 ordinary shares of 0.1 pence in Osmetech on the 22nd March 2006 and by
a further 25,000 ordinary shares of 0.1 pence in Osmetech on the 23rd March
2006.

The total holding of 24,109,657 shares comprises the aggregated holdings
controlled by GIL, GFM and GGP and represents approximately 18.29 per cent of
the Company's issued ordinary share capital.








This information is provided by RNS
The company news service from the London Stock Exchange

Looking good!!

Osmetech Plc Launch of eSensor
RNS Number:4965A
Osmetech PLC
28 March 2006



News Release

28 March 2006


Launch of eSensor Cystic Fibrosis Carrier Detection System


Osmetech plc is an international healthcare diagnostics group with two
divisions: Molecular Diagnostics and Critical Care, based on the OPTI range of
blood gas and electrolyte analysis products.


Osmetech Molecular Diagnostics has launched its eSensor Cystic Fibrosis Carrier
Detection (CFCD) test and its eSensor 4800 DNA Detection instrument at the
American College of Molecular Genetics meeting in San Diego, US, on 23-26th
March. Product shipments are expected to commence on schedule during the first
half of 2006.


The eSensor instrument and proprietary consumable system was developed by
Clinical Micro Sensors, Inc. (CMS) which was acquired from Motorola Inc. in July
2005.


eSensor

The eSensor system has the capability to perform relatively complex molecular
tests that require the simultaneous analysis of multiple genetic information.
Combining a universal platform design and a patented advanced electrochemical
detection technology, the eSensor System can detect and identify many different
targets at once.


The technology is protected by a strong intellectual property portfolio
comprising over 70 worldwide patents and has benefited from an investment of
over $100m by Motorola during their period of ownership.



FDA approval

In January 2006 Osmetech received 510(k) clearance from the US Food & Drug
Administration ('FDA') for its eSensor CFCD test and its eSensor 4800 DNA
Detection instrument platform.



This FDA approval is a first for a combined instrument and Cystic Fibrosis assay
consumable which incorporates a microarray with electrochemical detection. The
system qualitatively assesses the carrier status for Cystic Fibrosis for all
adult couples contemplating pregnancy.




In clinical trials, studies were conducted using the eSensor CFCD System
compared to bidirectional DNA sequencing. The method comparison studies tested
a total 486 samples. The eSensor CFCD system concordance with sequencing was
98.6% following repeat testing of samples which gave no-call, or 99.6% for
samples which gave a valid result. The comparison study analyzed 11,178
individual mutations. For all mutations the percent agreement between the
eSensor CFCD system and sequencing was 99.0% following repeat testing of samples
which gave no-call or 99.98% for samples which gave a valid result.



FDA submission pipeline

The combined instrument and microarray consumable is the platform which is being
used for future assay development. The next molecular diagnostics tests targeted
for FDA submission will be for CYP450 which will provide pharmacogenomic
information for better patient care and improved healthcare cost management.



James White, Chief Executive, Osmetech plc said,



'We are delighted to have achieved this important milestone with the launch of
the eSensor CFCD system at the American College of Molecular Genetics meeting in
San Diego. This is another important step in the controlled market release of
our first product to the molecular diagnostic laboratories.



'In the first 8 months of ownership of CMS, Osmetech has secured the first FDA
approval for the eSensor product and also obtained an FDA California State
License to manufacture product. The eSensor has now been launched and shipments
should commence on schedule during the first half of 2006.



'We are building on this excellent progress by continuing discussions with
strategic partners who are looking for cost effective and easy to use
instrumentation and consumables to work with other assays both in the healthcare
and non healthcare markets.



'We expect to be able to further demonstrate the considerable value within our
molecular diagnostics products and intellectual property portfolio in due
course.'


For further information:



Osmetech plc: James White, David Sandilands 020 7849 6027

Madano Partnership: Matthew Moth, Mark Way 020 7593 4000




Background information on Cystic Fibrosis

* With a carrier frequency of one in 25 and an incidence of one in 2,500,
Cystic Fibrosis is the most commonly inherited disease in the North American
Caucasian population.



* The American College of Medical Genetics and the American College of
Obstetricians and Gynaecologists recommended in 2001 that Cystic Fibrosis
carrier testing should be made available for all reproductive couples.



* Currently around one million tests are carried out annually in the US
alone.



* Most current tests are not FDA approved and testing locations are
restricted to those 300 institutions which are CLIA approved for running
complex testing where the testing institution is responsible for regulatory
obligations rather than the diagnostic company.



* The tests carried out in the large central laboratories are performed on
instruments that can cost in the region of US$100,000 and a high throughput
is required to justify the capital cost of the equipment.



* In addition the instruments are operated by qualified technicians capable
of interpreting the results.



* As a result of this each test is relatively expensive with each test
recharged at up to US$400 per test to those small to medium sized hospitals
requesting the tests to be run on their behalf.



This information is provided by RNS
The company news service from the London Stock Exchange
END

Osmetech unit launches Cystic Fibrosis
detection test and sensor

LONDON (AFX) - Osmetech PLC said Osmetech Molecular Diagnostics has launched
its eSensor Cystic Fibrosis Carrier Detection (CFCD) test and its eSensor 4800
DNA Detection instrument, and shipments are expected to commence on schedule
during the first half of 2006.
The eSensor system has the capability to perform relatively complex
molecular tests that require the simultaneous analysis of multiple genetic
information.
newsdesk@afxnews.com
lam

Small update to the header. Another busy month for OMH coming up

Bid up from the off - Plenty of stock being taken on at 22p, looks like another T trade buy is on its way.

Here's the IC take on the company.

AGM Date WEDNESDAY 3RD MAY

Looks like that's the order from the past few days...

Time Price Quantity Type Bid Offer Buy/Sell Total Buy Total Sell Total Unknown
04/04/06 13:07 23.0 957,000 VW 22.5 23.0 Buy 1,111,218 578,526 13,000

Another volume weighted trade BUY 836,417 @ 23.50p - the top end of the spread for the past week. Small time sellers seem to be filling these institutional purchases.

Hoare Govett to release a brokers note later today or next week.

Bangersman / dichpig / others

Got my copy of OMH accounts, they want me to vote on:

1 To Re-elect: J N G White director. ?
2 To Re-elect: G B Kuenster director. ?
3 To autherise directors to allot shares of up to 43,935 ?

Plus several other things what do you all think on these yes /no ?

The changes to the LTIP will be getting a 'No' from me, dangle the carrot slightly further away.

The rest of the resolutions are pretty obvious or just formality.

Next buy signal on OMH 3 box is only a tick away.

Looking good...

OMH (Osmetech) Tipped as a BUY in todays Sunday Telegraph
Sunday Telegraph (UK) - Apr. 23, 2006

KEEP an eye on Osmetech, the healthcare diagnostics group (24p).

Under the stewardship of James White, the company has developed into a business with sales, mainly thanks to a handful of acquisitions.

In results published last month, Osmetech revealed that sales for the eight months to December 31 were up by 78 per cent on the corresponding period.

Its investment in its critical care business is also paying off, with sales up by 64 per cent to $14.8m ( pounds 8.3m).

Since then it has announced the launch of its eSensor cystic fibrosis carrier detection (CFCD) test and its eSensor 4800 DNA detection instrument.

The eSensor system can be used to perform molecular tests that require the simultaneous analysis of multiple genetic information. Product shipments are expected to begin on schedule during the first half of this year, the company said.

We believe the shares look like good value. Buy.

The fuse has been lit...again.

More institutional buying taking place today.

Time Price Quantity Type Bid Offer Buy/Sell Total Buy Total Sell Total Unknown
25/04/06 15:11 25.0 1,000,000 O 24.5 25.0 Buy 2,024,664 238,725 5,020
25/04/06 15:18 25.0 825,000 O 24.5 25.0 Buy 2,901,664 238,725 5,020
25/04/06 10:16 25.0 500,000 O 24.5 25.25 Buy 570,031 92,432 0
25/04/06 10:24 25.0 250,000 O 24.5 25.25 Buy 970,031 95,338 0
19/04/06 16:00 24.0 250,000 O 22.5 24.5 Buy 339,399 223,584 15,000
19/04/06 19:02 24.0 250,000 B 22.5 24.5 ? 0 0 0
25/04/06 10:21 25.0 100,000 O 24.5 25.25 Buy 720,031 95,338 0
24/04/06 16:56 25.0 100,000 O 23.0 26.0 Buy 422,530 171,071 305,000

Link

copycat

(lol)
There's an ascending triangle pattern occurring. So when 25p breaks the move to 30p should be even more rapid.
Ascending triangles
free stock charts from ADVFN.COM

I am a holder in OMH and have been for many years, I hope they do break upwards, but your chart shows 3 ascending triangles the first 2 break down !

Lets hope it's third time lucky then. Looking at yesterdays trades someone feels confident!

So it was UBS AG that were buying. Looking good!Osmetech PLC
26 April 2006

Osmetech plc ('Osmetech' or 'the Company')



The Company was notified, on 25th April 2006, that UBS AG has an interest in
8,825,000 ordinary shares of 0.1 pence each in Osmetech.

The total holding represents approximately 6.70 per cent of the Company's issued
ordinary share capital.

IDEXX Laboratories First Quarter 2006 Earnings Conference Call
Friday, April 28, 2006 - 9:00 AM ET

(Might give an update on VetStat sales and progress of CC platform)

AGM Statement

RNS Number:3112C
Osmetech PLC
03 May 2006





3 May 2006



Osmetech plc - AGM Statement

Osmetech plc, the international healthcare diagnostics group will provide the
following update during its Annual General Meeting at 11:00am today:

Critical Care Division

Our Critical Care business continues to build on the sales growth achieved in
2005 and as expected, demand in the current year for the Division's OPTI range
of blood gas analysis products has remained strong in both the human and
veterinary markets.

For the remainder of 2006 we expect the healthy levels of demand in the Critical
Care Division to continue and therefore be another year of growth for this
division.

Molecular Diagnostics Division

Osmetech continues to make significant progress and remains on schedule with its
new product launches. As planned, in March we launched our FDA approved eSensor
Cystic Fibrosis Carrier Detection test and eSensor 4800 DNA Detection instrument
and later this month we will launch our OPTI TUBE product for use in the Roche
LightCycler as a cost-effective and safe alternative to the Roche glass
capillaries. Our OPTI GENE instrument and proprietary consumable system for the
rapid detection of DNA and RNA targets will be available for sale in June,
although the product will be fully launched with thrombophilia assays at the
American Association of Clinical Chemists (AACC) Conference in Chicago in July.

We have been delighted with the initial stages of product commercialisation in
this fast growing market sector. We plan to replicate the successful Critical
Care business model of selling instruments and proprietary tests primarily to
small and medium sized hospitals across the globe through our well established
distribution networks.

The installation of instruments will provide the basis of future revenues by
introducing a wider range of tests, developed both by Osmetech and third
parties. In addition, our instruments have significant potential in other
markets, such as veterinary, environmental and forensics, which we would look to
exploit through strategic partnerships.

Outlook

The Board remains confident that 2006 will be a strong year for Osmetech.

Our Critical Care Division is on track to achieve another profitable performance
and will continue to provide a strong base and proven infrastructure for the
Group overall as we introduce products in the molecular diagnostics market.

We fully expect to be able to demonstrate the value of our strong position and
the considerable opportunities that exist in the exciting molecular diagnostics
market as we enter the important commercialisation phase.

Ends

For further information:

Osmetech plc +44 (0)207 849 6027
James White, Chief Executive Officer
David Sandilands, Chief Financial Officer

madano partnership +44 (0)207 593 4000

Matthew Moth

Mark Way

The installation of instruments will provide the basis of future revenues by
introducing a wider range of tests, developed both by Osmetech and third
parties. In addition, our instruments have significant potential in other
markets, such as veterinary, environmental and forensics, which we would look to
exploit through strategic partnerships.

We fully expect to be able to demonstrate the value of our strong position and
the considerable opportunities that exist in the exciting molecular diagnostics
market as we enter the important commercialisation phase.

Another large holder has shown their hand. 3%+ holders and directors now control c63% of the issued shares of the company.

Osmetech PLC
05 May 2006

Osmetech plc ('Osmetech' or 'the Company')



The Company has been notified that following the acquisition of 1,100,000
ordinary shares, Universities Superannuation Scheme Limited now has an interest
in 4,780,000 Osmetech shares. The shares are registered under Chase Nominees Ltd
(USS).

The total holding represents approximately 3.627 per cent of the Company's
issued ordinary share capital.

The latest freebie from MW, which im sure he wont mind me posting here.

Catching the Cash

There has been nothing but good news from Osmetech (OMH) this year, yet the shares are languishing at 22.5p to 23.5p, way down from the 33.5p they touched in January. Though I hate to argue with the market, that fall looks foolish.

The price has not been helped by the clumsy surprise (certainly to the company) sale of 21m shares at 20p as Motorola simply chucked stock onto the market to clear the books (see my archives Money Down The Drain January 26). Nor has it been helped by the warning repeated with the March 21 figures that further funding would be required later this year to finance the launch of new products.

The share dump will not happen again. Motorola was simply recovering a little cash after effectively giving Clinical Micro Sensors (CMS) away in another of the shrewd cut-price purchases engineered by Osmo chief executive James White. The sale was executed, some say badly, by former broker Evolution. ABN Amro is now in place as a bright new broker with US connections (Osmos business is now firmly in the US).

The funding? This is intriguing. There have been some shrewd posts on the ADVFN bulletin board. These reason that the companys major institutional shareholders would not want more shares issued at current prices, effectively them, and might be keen to support a placing, perhaps at more than the current level.

Gartmore has over 18% of Osmo, and Schroders more than 14%. It seems that they are heavily committed to the story, and there is speculation that they might, indeed, be ready to support the business at a premium. There is also the possibility that Osmo could raise cash by selling some of the intellectual property which came in with CMS last summer. Remember, Motorola effectively acquired it for $280m in 2000, then spent $100m on research and development. Such a business ought to have stacks of value tucked away.

And if it cannot sell something, maybe Osmo could generate some cash by bringing in a partner somewhere.

All of this is sheer speculation, of course, but it does reinforce the notion that the Osmo management is acutely aware of the share price and reluctant to countenance further dilution, if at all possible.

When will money be raised? It is not clear. Will it be raised at this price? Probably not. Maybe the new broker can help here. An updated research report would help.

Bears and short sellers please note we are not dealing here with a company which makes money. It reported pre-tax losses of 5.4m for the eight months to December 31, and is forecast to lose around 10m for 2006. So there is ample room for non-believers to bash away, and it will take until 2008 before decent profits emerge.

That does not mean there is not significant value in the company as it stands. Take the critical care division, the bit built around the OPTI blood gas analysis business. That makes machines, and sells consumables for those machines. It is growing fast, with sales of 5.58m (up 78%) in the eight months to December 31. They are probably running close to 10m in the current year. Comparable businesses in the US have sold for between 2.8 and five times revenues. So the critical care division, which would be profitable if it could be stripped out of Osmo, is worth the current whole company market capitalisation of 30m on its own.

Critical care is going great guns, selling more machines which lead to more consumables sales. It sold perhaps 1,000 machines into the veterinary market last year, thanks to a link with veterinary distribution giant IDEXX, and could sell more this year. Each veterinary machine probably uses three consumables a day, against one a day in hospitals.

The human business specialises in near-patient testing (testing in the hospital or clinic, instead of taking samples to be not sent away for processing) and there are two new product launches set to help deliver growth this year the OPTI R multi-use consumable for higher usage customers, and OPTI LION, a low cost electrolyte only instrument. So OPTI looks good and growing.

The real excitement, however, lies with the molecular diagnostics division, for which there is nothing in the share price if you accept OPTI is worth 30m. This bears the research and development costs (there are 50 or 60 people working on the new P450 test alone), but has taken Osmo into an exciting and fast-growing niche market which could be very valuable.

Again, the bears could suggest that since Osmo picked up the businesses which largely comprise this vision for practically nothing, they are worth nothing. But they have had maybe half a billion dollars of research and development pumped into them and since Osmo bought in, have succeeded in getting FDA approval for products.

In January, Osmo won FDA approval for a test to detect cystic fibrosis, and for the e-Sensor DNA Detection machine which runs that test. The test produced results which achieved remarkable success. There are around one million tests for cystic fibrosis in the US each year, mostly carried out by qualified technicians on $100,000 machines in large central laboratories to which the samples are sent. They are charged at perhaps $400 or more a time.

The Osmo e-Sensor will go to hospitals which will be able to test in-house. Machines will start being installed in the first half of this year. Perhaps ten or twelve will be placed in 2006 running tests, with revenues generated by the consumables.

But the e-Sensor will not be confined to the cystic fibrosis tests, which are likely to be given to all childbearing couples. It can accommodate a variety of relatively complex molecular tests, analysing multiple genetic information, able to detect many different targets at once. There is intellectual property protected by over 70 international patents.

The next e-Sensor test for which Osmo is seeking FDA approval will be the Cytochrome P450 (CYP 450) pharmacogenomics assay. This should yield valuable information on drug metabolism, basically determining how individuals will react to different drugs, thus helping determine safety and dosage. That opens the way to personalised drugs a major advance.

Roche has such a test which sells at $800 a time. Hopefully, the Osmo version will win FDA approval next year. It should handle three major separate tests, with the first directed at Warfarin, which treats blood clotting, and is used by perhaps 20m people each year. Thousands suffer an adverse reaction each year.

Alongside producing these specific consumables for the e-Sensor, Osmo is talking to pharma companies who wish to run their tests on the machine. Others have the assays, but lack a suitable instrument.

In addition, Osmo expects in June to launch the OPTI GENE system, a machine for detecting DNA and RNA targets with simple assays. This uses technology developed by an earlier acquisition company, Molecular Sensing. It should provide results within 30 to 45 minutes using a single patient disposable cartridge. Once again, it is designed for near-patient testing in medium to smaller hospitals. The initial launch will take in thrombophilia assays.

In May, the company should also launch the OPTI TUBE. These are specially designed plastic tubes to replace the glass tubes now used by pharma giant Roche. There are some 50m glass tubes sold each year. The OPTI alternative costs a fraction of the Roche price, and is much safer. Roche has been granted a non-exclusive licence to make and sell it.

There is, then, a raft of new products about to come onstream. They range from the low-tech, low-cost but high volume items like OPTI TUBE to highly sophisticated machines and assays. These are all, arguably, in the share price for nothing.

If they take off, they could be worth a multiple of the current share price. But it will take a year or two for them to win a decent market share, and they will require financing along the way.

Tiny Osmo bought these much bigger opportunities for a song. Raising the full working capital required to get them to market would have been quite a stretch at the time. Now they are reaching the market, raising extra cash for the final push looks less daunting.

Clearly there are risks. There is an exciting list of new products with great potential, but they are not yet selling. They have not penetrated the market. The machines might well be given away so that Osmo can establish them in place, and then earn from high margin consumables.

Such a business might appear too complex and foreign to many UK investors. The research and development is taking place in the US, the main initial market, though there are links in the UK and Europe.

Clearly Osmo has some UK believers ready to back the business to take it to the next stage. New broker ABN Amro might be better able than Evolution to exploit market interest in America, where such companies are better understood.

As the products start to penetrate the market, and as worries about future funding are eliminated, the shares could advance sharply. But, once again, they are not without risk.

http://news.ft.com/cms/s/5d32d9d6-e643-11da-a36e-0000779e2340.html
Osmetech, the healthcare diagnostics group, firmed up 1.1 per cent to 22p after house broker ABN Amro initiated coverage with a buy recommendation and a 30p target price. The broker believes strong newsflow over the next 12 months will help highlight the value of Osmetechs molecular diagnostic assets.

http://www.timesonline.co.uk/article/0,,2095-2168219,00.html

USS increased their position

Osmetech PLC
26 May 2006

Osmetech plc ('Osmetech' or 'the Company')

The Company has been notified that following the acquisition of 720,000 ordinary
shares, Universities Superannuation Scheme Limited now has an interest in
5,500,000 Osmetech ordinary shares. The shares are registered under Chase
Nominees Ltd (USS).

The total holding represents approximately 4.17 per cent of the Company's issued
ordinary share capital.

MajorShareHolders No. Shares(%) Gartmore 22,016,240(16.70) Schroder 18,874,284 (14.32) UBS AG 7,700,000(5.84) Universities S S LTD 5,500,000(4.17) Pershing Keen 5,870,773 (4.45) Roche 2,444,688 (1.8) Total 62,405,985(47.28)

Looks as if the three blind mice have in fact got perfect eyesight.

Share price down to a lowly 18.5p after news of yet another fund raising exercise - diluting existing shareholdings and raising the number of shares in issue by over 50%.

Yuk.

well the rampers have shown they lack any sort of judgement. RAMP RAMP here and on competitors site. If anyone dared to question their so called wisdom they were banned from posting. This episode shows what idiots they are. I continue to hold.

Back to 30p+ very soon...IMHO.

MajorShareHolders No. Shares(%) Gartmore 22,016,240(16.70) Schroder 18,874,284 (14.32) UBS AG 7,700,000(5.84) Universities S S LTD 8,900,000(6.75) Pershing Keen 5,870,773 (4.45) Roche 2,444,688 (1.8) Total 65,805,985(49.86)

Can you keep that table up to date please!

MajorShareHolders No. Shares(%) Gartmore 22,016,240(16.70) Schroder 18,874,284 (14.32) UBS AG 17,985,541 (13.65) Universities S S LTD 8,900,000(6.75) Pershing Keen 5,870,773 (4.45) Roche 2,444,688 (1.8) Total 76,091,526(57.67)

after todays buying i suspect it will be out of date again very very soon!

Buy signal triggered for OMH (Osmetech) on the 3 box. Upside price objective works out around 33p!! Good low risk / high reward entry point .

Rated as a BUY in IC this week by the way, (or Good Value) can't remember which.

From the IC

23 June 2006

Osmetech in cash call


Osmetech shares fell 4 per cent after the company announced that it's raising 12.8m at 18p, an increase of 53.9 per cent in its share capital. The new funds will provide working capital for the company, which admitted that without the fund-raising it would be "unable to trade much beyond August 2006". Management says that it needs the cash to help fund new product launches, and improve its negotiating position in out-licensing opportunities.



Osmetech stated at its full-year results in March that it would need to raise funds. So, at 18p, the shares remain good value. BUY

SCREAMING BUY...

Looks like the major holders table will need another update...
http://moneyam.uk-wire.com/cgi-bin/articles/200607041225366403F.html

MajorShareHolders No. Shares(%) Gartmore 22,016,240(16.70) Schroder 18,874,284 (14.32) UBS AG 17,985,541 (13.65) Universities S S LTD 8,900,000(6.75) Pershing Keen 5,870,773 (4.45) BCSSS 4,301,289(3.26) Roche 2,444,688 (1.8) Total 80,392,815(60.93)

Trading Statement

RNS Number:9033F
Osmetech PLC
10 July 2006



Osmetech plc - Trading Update

Osmetech plc, the international healthcare diagnostics group will provide the
following update during its Extraordinary General Meeting at 11:00am today:

During the first six months of 2006, the Group has continued to build on the
strong sales growth achieved in 2005. Sales for the 6 month period ended 30 June
2006 are 36% ahead of the corresponding period in 2005.

The majority of sales relate to the Critical Care division where sales exceeded
$8.6m, up by 34% on the corresponding period in 2005, with sales increasing in
both human and veterinary markets.

As planned, in the first half of the year, Osmetech's Molecular Diagnostics
Division launched its FDA approved eSensor Cystic Fibrosis Carrier Detection
test and eSensor 4800 DNA Detection instrument and OPTI TUBE product for use in
the Roche LightCycler as a cost-effective and safe alternative to the Roche
glass capillaries. Our OPTI GENE instrument and proprietary consumable system
for the rapid detection of DNA and RNA targets will be launched with
thrombophilia assays at the American Association of Clinical Chemists (AACC)
Conference in Chicago later this month.

We are confident of further sales growth for the Group in the second half of the
year. We expect our Critical Care division to report a record sales performance
during the next six month period with a growing contribution from our new OPTI
LION and OPTI R instruments and further strong sales growth of the VetStat
product by our distribution partner, IDEXX, in the veterinary market. We also
expect to report early commercial success with our new molecular diagnostics
products as we start to build a significant presence in this rapidly growing
market.

Ends

Osmetech says US biotech fund Efficacy holds almost 9 pct of co

LONDON (AFX) - Diagnostics company Osmetech PLC said the Efficacy Biotech
Fund of California-based Efficacy Capital Ltd now owns 18 mln shares or 8.876
pct of the company.
newsdesk@afxnews.com
ak

COPYRIGHT

Copyright AFX News Limited 2005. All rights reserved.

MajorShareHolders No. Shares(%) Gartmore 22,016,240(10.86) Schroder 29,171,506 (14.32) UBS AG 21,518,671(10.61) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 107,921,878(53.21)

UBS Increase of Holding

MajorShareHolders No. Shares(%) Gartmore 22,016,240(10.86) Schroder 29,171,506 (14.32) UBS AG 23,797,239 (11.73) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 110,200,446 (54.34)

UBS Increase of Holding

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 29,171,506 (14.32) UBS AG 23,797,239(11.73) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 119,463,550(58.91)

Gartmore Increase of Holdings

Interim Results Wednesday 13th Sept

Ne UK smallcap opening - Osmetech higher on Evanston deal
AFX


LONDON (AFX) - Early progress was seen in Osmetech, 1-1/2 pence firmer at 18, after news that the group has signed a non-exclusive commercial licence with Evanston, Illinois-based Ohmx Corporation to Osmetech's self-assembling monolayer nanotechnology for biosensor use.

newsdesk@afxnews.com

Osmetech PLC signs license

RNS Number:4806K
Osmetech PLC
16 October 2006


Osmetech licenses pharmacogenetic marker for P450-CYP2D6 from EPIDAUROS


Bernried, Germany - October 16, 2006, EPIDAUROS Biotechnologie AG, a leading
provider of pharmacogenetic solutions located in Bernried near Munich, and
Osmetech plc, an international healthcare diagnostics group, jointly announced
today that Osmetech has signed an agreement for a non-exclusive commercial
license to EPIDAUROS' patent application on a specific biomarker related to the
Cytochrome P450 CYP2D6. Financial details are not disclosed.

The agreement covers the genetic variant 2988G>A in the CYP2D6 gene. This
variant could be used in combinatorial analysis with further genetic variants of
CYP2D6 as a predictive marker for impaired enzymatic function putting patients
at higher risk for non-responsiveness or adverse drug reactions. CYP2D6 plays a
role in the metabolism of 25% of the most commonly prescribed drugs to date.
Therefore, the sound analysis of CYP2D6 is important in the course of clinical
drug development to make drug therapy safer and more efficacious.

James White, CEO of OSMETECH added, "This deal marks an important move forward
as we look to gain access to the validated content that exists in the important
area of pharmacogenomics. With the Cystic Fibrosis product already on the market
and our earlier license from LGC, we are in a strong position to take our FDA
cleared electrochemistry-based eSensor(R) array platform into the market with
the launch of our first pharmacogenomic products."

Michael Lutz, CEO of EPIDAUROS added: "We are delighted that Osmetech will use
EPIDAUROS' intellectual property with respect to the variant 2988G>A of CYP2D6
to develop value-adding diagnostic products. This agreement is clearly another
milestone in our strategy to fully exploit the commercial potential of our
existing patent portfolio. We are confident that other companies will require
appropriate licenses on this genetic marker shortly. We also look forward to
exploring additional business opportunities with Osmetech in the near future."


Contact EPIDAUROS:

Dr. Michael Lutz Dr. Stephan Reschauer
Chief Executive Officer Director, Patents & Licensing
Phone: +49 (0)8158 9985 0
Fax: +49 (0)8158 9985 48
Email: contact@epidauros.com

Contact Osmetech plc:

Edward O. Kreusser, Esq.
Vice President Intellectual Property and Legal Affairs
Phone: +1 626 463 2000 ext. 8017
Fax: +1 626 463 2012
Email: Ed.kreusser@osmetech.com


About Osmetech plc
(www.osmetech.com)

Osmetech plc is an AIM-listed public company on the London Stock Exchange. The
company is a fast developing, international diagnostics business with operations
in Atlanta, Boston and Pasadena in the US, serving the high growth, near patient
testing market targeting small to medium sized hospitals. Osmetech operates in
two business areas, namely Molecular Diagnostics and Critical Care Diagnostics.
Osmetech has launched eSensor(R), an FDA cleared electrochemistry-based array
system, for Cystic fibrosis carrier detection and will launch a number of
pharmacogenomic assays utilizing our proprietary technology in the near future.


About EPIDAUROS Biotechnologie AG
(www.epidauros.com)

EPIDAUROS Biotechnologie AG is a leading provider of tailor-made pharmacogenetic
solutions in the area of clinical drug development. The company investigates the
individual genetic profile that influences a person's response to a drug in
order to make drug development and therapy safer and more efficient. EPIDAUROS
examines and characterizes variations (polymorphisms) of genes that encode for
drug transporter proteins, drug metabolizing enzymes and drug targets, e.g.
receptors.

EPIDAUROS' business activities range from scientific pharmacogenetic
consultancy, conduct of logistics for sample collection and shipment, sample
processing and genetic testing in its own laboratory, up to data analysis and
submission-ready reporting. In addition, provision of services includes
development of new assays for genetic testing and extensive analysis of
pharmacogenetic data, e.g. with regard to haplotypes (linked genetic markers).

EPIDAUROS explores new polymorphisms with pharmacogenetic relevance in close
collaboration with leading academic institutions. In addition, the company also
offers a concept for the development of drugs with companion diagnostics to the
pharmaceutical industry. Moreover, EPIDAUROS develops genetic tests for routine
use together with diagnostics companies.


For further information, please contact:

EPIDAUROS Biotechnologie AG
Am Neuland 1, D-82347 Bernried
Phone: +49 (0)8158 9985 0
Fax: +49 (0)8158 9985 48
Email: contact@epidauros.com
www.epidauros.com

Osmetech Inc.
DBA as Clinical Micro Sensors
757 South Raymond Street
Pasadena, CA 91105
USA
Phone: +1 626 463 2000
Fax: +1 626 463 2012
Email: information@osmetech.com
www.osmetech.com



This information is provided by RNS
The company news service from the London Stock Exchange

END
NRAGUGRPUUPQGMW

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 30,516,506(15.05) UBS AG 23,797,239(11.73) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 120,808,550(59.56)

Schroder Investment Management Increase Stake

Bangersmam,

Is this the only share you own ?????? Talk about flogging a dead horse, since the thread was started by you nearly a year ago the share price has dropped by around 10% despite you continually trying to scrape up interest in it.

Do what I did - take the loss on the chin and recoup the money in more viable companies.

Dont judge others by your own poor trading standards, i have no loss to take- only profits.

Looking good for a further breakout soon.

hobbsts

Selling up was a very stupid thing to do...

everyone is entitled to their opinion ...................I personally did not want to hold for year upon year to recoup my loss. You win some, you lose some. Holding shares is all about making money and not getting emotionally involved with the company as is what is happening on this thread.

A few more clueless holders taken out in yesterdays tree shake- paving the way for further rises.

Looking good for 25p soon!

hobbst, what a clueless tosser

DITCHPIG

Good of you to let the world see what a great command you have of the english language.

hobbst, what a clueless tosser

Been reading all the personal abuse that both DITCHPIG and bangers(mam) get up to on ADVFN, while ramping OMH - their only shareholding. No wonder that people on that website are fed up with their antics and have even set up a thread to try and exclude people like these, in order to get a level debate.

Come on Money AM, must be time to get rid of these idiots from your bulletin boards.

What a spastic! Why should MoneyAM give a t0ss what happens on a rival website. LOL.

Come on Money AM, this poster is deliberately out to ruin a thread i've set up for research/info etc on OSMETECH.
As an HTML novice the header alone took me a week to sort out the coding.

The rival site gives the thread creator the option to ban idiots like hobbst from their own threads, this way all the hobbts's (gerry2's) can join force on one alternate thread and talk crap all day and leaving a serious (my) thread for investors.

Perhaps genuine users should be given this same 'moderate' option here?

Well, lets face it, not much serious debate happens on your thread as you spend most of the time abusing contributors !!!!!!!!!!

By the way, I am not gerry2 on ADVFN. Glad to see that he treats your abuse the same way as I do ........ yeh, whatever.

hobbst, what a clueless tosser

Osmetech go live with their new quality and customer management systems.

http://www.pilgrimsoftware.com/press/Pasadena-Go-Live-Pilgrim.shtml

and a presentation about the process. Read the slides so you can understand why it is necessary to use these tools.

http://www.advamed.org/publicdocs/pilgrim_study.pdf

Osmetech at the Deutschen Gesellschaft f Anthesiologie und Intensivmedizin (DGAI) wird vom 05. 08. May 2007 in Hamburg.

http://www.dac2007.de/aussteller/dac2007-aussteller-086.htm

..............looks like this is going to be a very lonely thread for DITCHPIG and bangersmam to ramp this dog of a share...... hope you are both very happy together.......bye bye

hobbst, what a clueless tosser

LOL

hobbst, what a clueless tosser

LOL

One of Moneyam;s thickest. A complete pratt.


hobbst - 10 Nov 2006 14:22 - 138 of 138 (squelched)

Price starting to creap back up after the recent profit taking. 30p seems a real possibility from the next leg of the breakout - Finbonacci projection also puts this area as the next price target.

Looking Good.

when the price has crept back to recent highs further good news from the company should propel it back to the 30-40p level. Given that we are expecting a strong results update In Januray the start of 2007 could be very interesting!

hobbst your totally correct in your observations.

Motoring today. Up 8% plenty more to come.
Lookng good

Incidentally the price hasn't stop motoring since the thread 'zits' popped up.

60% in 6 weeks will do for starters, with no fund raising needs (like last year) the resistance at mid 30p's should be a piece of cake.

RNS Number:0992M
Osmetech PLC
15 November 2006



Osmetech increases patent holdings November 15, 2006


Pasadena, California, USA - Osmetech Molecular Diagnostics (Osmetech), a fast
developing, international diagnostics business serving the high growth, near
patient molecular testing market, today announced that it has been granted a UK
patent covering its OPTI TUBETM plastic capillary product. The grant of the UK
patent follows the recent registration of a German Utility Model which also
covers Osmetech's innovative plastic vessel. The tube is made from cyclic olefin
and has excellent rigidity, optical and thermal properties making it the product
of choice for PCR thermal cycling and other applications that traditionally
employ breakable glass. Adding to this versatility and novelty, Osmetech also
sells a carousel housing for the OPTI TUBEs that fits the Roche Lightcycler(R).

The new patent, GB 2409659, is just one of a number of patents issued to
Osmetech in the last six months, according to Edward Kreusser, Osmetech's VP of
Intellectual Property and Legal Affairs. Osmetech now owns or holds exclusive
rights to some 130 patents worldwide (70 US) mostly in the field of
electrochemical detection for biological entities such as nucleic acids and
proteins which offers significant advantages over other methods.

Osmetech's growing patent estate boasts tens of millions in investment over the
last decade from Motorola, Caltech, Harvard University and the University of
North Carolina who continue to have a vested interest in the technology and are
pleased to see the great commercial potential of the portfolio become a reality.

This latest development builds on momentum achieved earlier this year when
Osmetech received FDA approval to launch its eSensor(R) electrochemistry-based
array system for cystic fibrosis carrier detection. In addition to other
projects, Osmetech plans to follow with a battery of related pharmacogenomic
CYP450 assays emploing the same electrochemical detection platform.

Contact Osmetech:

Edward Kreusser, Esq.

Reckon we could see a chart breakout today.

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 27,966,506(13.79) UBS AG 23,797,239(11.73) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 118,258,550(58.31)

Nice chart breakout under way.

Looks like it is going to pop. I wonder if some deal was hacked at Medica or AMP last week?

New trade marks for Molecular Products have been registered recently.

Say hello to TRITON and IMPLUSE. Interestingly they are registered under the Molecular Diagnostics brand rather than just Osmetech.

Word Mark TRITON
Goods and Services IC 009. US 021 023 026 036 038. G & S: Medical invitro diagnostic devices and modules that employ electrochemical detection of target analytes
Standard Characters Claimed
Mark Drawing Code (4) STANDARD CHARACTER MARK
Design Search Code
Serial Number 77038992
Filing Date November 7, 2006
Current Filing Basis 1B
Original Filing Basis 1B
Owner (APPLICANT) Osmetech Molecular Diagnostics CORPORATION DELAWARE 757 S. Raymond Ave. Pasadena CALIFORNIA 91105
Type of Mark TRADEMARK
Register PRINCIPAL
Live/Dead Indicator LIVE




Word Mark IMPULSE
Goods and Services IC 009. US 021 023 026 036 038. G & S: Medical invitro diagnostic devices and modules that employ electrochemical detection of target analytes
Standard Characters Claimed
Mark Drawing Code (4) STANDARD CHARACTER MARK
Design Search Code
Serial Number 77038972
Filing Date November 7, 2006
Current Filing Basis 1B
Original Filing Basis 1B
Owner (APPLICANT) Osmetech Molecular Diagnostics CORPORATION DELAWARE 757 S. Raymond Ave. Pasadena CALIFORNIA 91105
Type of Mark TRADEMARK
Register PRINCIPAL
Live/Dead Indicator LIVE

Major holders table updated. UBS being the latest buyers

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 27,966,506(13.79) UBS AG 25,346,239 (12.5) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 119,807,550 (59.08)

Todays Breakout of the inverse head and shouldes give a short term price target of c 32p

Nice continuation of the breakout today.

looking good

Moving up again.

OMH - now Gartmore's second largest holding!

http://www.advfn.com/p.php?pid=nmona&cb=1165236703&symbol=gsm&article=0018245385

Nicely on track for the c32p price projection based on the highly accurate inverse head and shoulders formation.

Trading Statement due early 2007

Some big BUY's put through after hours.

Time Price Quantity Type Bid Offer Buy/Sell Total Buy Total Sell Total Unknown
07/12/06 17:06 27.027 500,000 B 25.0 28.0 Buy 856,911 748,631 380,000
07/12/06 16:34 27.0 500,000 O 25.0 28.0 Buy 1,431,911 748,631 380,000
07/12/06 16:34 27.0 500,000 O 25.0 28.0 Buy 1,931,911 748,631 380,000
07/12/06 17:11 26.92 425,000 O 25.0 28.0 Buy 2,356,911 748,631 380,000

<>

Are we expecting the results at the end of january bangers?

I should think around that time but there's the Trading Statement to look forward to first! And perhaps more BIG news in the mean time!?

Considering in July OMH were forecasting 'record sales performance
during the next six month period' i would expect this TS to be more than upbeat.

Would you expect the price to rise prior to the TS & results then?

So potentially we are looking at another 6 weeks of continues rises?

Yep, and no reason why it should stop then.

Some of the largest trades from this week.

Time Price Quantity Type Bid Offer Buy/Sell Total Buy Total Sell Total Unknown
08/12/06 16:39 27.88 710,000 T 27.25 28.0 2,326,622 436,644 55,000
07/12/06 17:06 27.027 500,000 B 25.0 28.0 Buy 856,911 748,631 380,000
07/12/06 16:34 27.0 500,000 O 25.0 28.0 Buy 1,431,911 748,631 380,000
07/12/06 16:34 27.0 500,000 O 25.0 28.0 Buy 1,931,911 748,631 380,000
08/12/06 09:03 26.92 425,000 L 0.0 0.0 ? 0 0 0
07/12/06 17:11 26.92 425,000 O 25.0 28.0 Buy 2,356,911 748,631 380,000
08/12/06 13:39 27.875 200,000 T 27.5 28.0 Buy 1,432,991 373,072 55,000
08/12/06 09:14 28.0 200,000 T 27.5 28.0 Buy 667,890 8,800 0

Quiet here, soooooo

The men in suits have been at Osmo HQ, due diligence seems to be buzz word.

The gossip is that there are "new investors" floating about. Some of the ex CMS die hards think they have seen it all before and are concerned they could be getting sold off and made redundant again. Time will tell

4 possible scenarios are
A deal for or fire sale of the OPTIgene technology to Idexx and the closure of the Boston office.
Another placing to fund further development / purchase of new technology.
A major deal to supply XT-8 equipment.
A major co taking a significant stake or complete buy out.

Take your pick.
I wonder how long it will be before any one notices this. he he


Anyone notice that OPTIGene, genesensor whatever has vanished from the product list?

Maybe even two, as it seems there has been a few big buyers competing for stock.

Looking very strong now.

The thread dimwits have gone quiet all of a sudden. Cant think why?

the price we are at now offered resistance in jan 06 and april 05, we really need some good news to get past 30p and hold there then upto 34p.

But can trend lines and past resistance areas be relied upon due to the increased number of shares since those times?? Either way not long to the trading statement early '07 and of course there's always the chance of something else BIG(!?) before then!?

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 27,966,506(13.79) UBS AG 24,261,239(11.96) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 118,722,550(58.54)

"Austin-based Luminex Corp. and Tm Bioscience Corporation today announced a definitive agreement for Luminex to acquire Tm Bioscience Corporation, a leader in the commercial genetic testing market."
Luminex to acquire molecular diagnostics company

(Thanks to Bucketfull on AFN)

Thanks to Bruce (AFN)

Citywire tip - just out!
http://www.citywire.co.uk/News/NewsArticle.aspx?VersionID=87844&NewsPage=2

The recent announcement by molecular diagnostics testing company Osmetech (OMH) regarding the sale of its Critical Care division to IDEXX has led to a surprising 11.5% fall in its share price to a current mid-price of 25p.

In all fairness the shares experienced an excellent run prior to the disposal, with a gain of almost 80% from its lows back in September.

The company revealed it had sold the Critical Care Division for $44.9 million (22.9 million), a 15-fold increase from its original purchase price back in 2003. The company also said the cash balance at the end of November was 7.98 million.

Should Osmetech obtain shareholder approval at its extraordinary general meeting on 9 January, then before any cash burn, the company should be sitting on more than 30 million in liquid reserves. And with a market capitalisation of 50 million, the enterprise value is just 20 million.

The company will now specialise solely in molecular diagnostics which it promotes as the fastest growing sector of the global diagnostics market.

Osmetech intends to use the sale proceeds to develop and commercialise its existing product pipeline, secure licensing agreements and explore acquisition targets in the molecular diagnostics field. It may even consider entering non-healthcare markets to leverage its intellectual property.

It is interesting to note that since the disposal, UBS increased its holding in Osmetech by 785,000 shares to 12.35% of the company. And the last trade reported on 18 December was for 785,000 shares at 30.5p, a trade I suspect that belongs to UBS. On that basis it appears that the smart money is prepared to pay top dollar for the stock.

Although a comparison with fellow diagnostic company Proteome Sciences (PRM) is a bit tenuous, the difference in sheer valuations is startling. As of its last set of results in September, Proteome had just 900,000 cash with a 2 million loan facility.

The company is capitalised at 80 million suggesting an enterprise value of 79 million, barring non-cash assets. Osmetechs is just 20 million come mid January. Given the companys prospects and its relative low valuation, long positions should be considered at market with a stop-loss based on a close below 21p.

.

anyone read the Express today ?

There has been an announcement from the company this am...not reported on here.

wow !
where is everyone, thought this thread would be alive today!!!!!